Combination of Foley/Dinoprostone Gel versus Foley/Misoprostol for early expedited delivery in women with severe preeclampsia undergoing Induction of labor more than 34 weeks gestation - NIL

Start Date21 Dec 2025

Sponsor / Collaborator

Jawaharlal Institute of Post Graduate Medical Education & Re

ISRCTN16808684

/ RecruitingNot Applicable

Concurrent Foley catheter and controlled-release dinoprostone vaginal insert versus Foley catheter for labour induction in obese nulliparas: a randomized controlled trial

Start Date01 Oct 2025

Sponsor / Collaborator

University Malaya Medical Centre

CTRI/2025/04/083785

/ Not yet recruitingNot ApplicableIIT

A comparative study to evaluate the efficacy and safety of dinoprostone and tacrolimus following dermabrasion in the treatment of stable vitiligo. - NIL

Start Date04 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Dinoprostone

100 Translational Medicine associated with Dinoprostone

100 Patents (Medical) associated with Dinoprostone

37,073

Literatures (Medical) associated with Dinoprostone

01 Jun 2026·International Orthodontics

Three pharmacological agents for acceleratory orthodontic tooth movement and subsequent relapse: A randomized controlled animal study

Article

Author: Hamed, Samar Ali ; Fouda, Ahmed Maher ; Montasser, Mona Abdelaziz ; Grawish, Mohamed E ; Mohammad, Mohammad Hasan

OBJECTIVES:

To investigate the effects of submucosal injections of acceleratory orthodontic materials and the subsequent relapse rate. No previous study has compared the effects of different acceleratory agents on post-retention relapse. Orthodontic tooth movement (OTM) in rats was evaluated over 4 weeks, followed by 2 weeks of retention and 2 weeks of relapse.

MATERIAL AND METHODS:

Randomization: The trial included 105 rats divided randomly with a blinded second author into five equal groups.

INTERVENTIONS:

Group I (negative control) rats weren't subjected to OTM or any acceleratory agents. Group II (positive control) rats underwent OTM without receiving any tested injectable materials. Groups III, IV, and V received the same OTM as Group II, accompanied by injections of corticosteroid, vitamin D, and PGE₂, respectively. The primary outcome: Tooth movement was measured at predetermined intervals, and histological assessments were performed after euthanasia. Statistical analysis was done using One-way ANOVA then post-hoc Tukey and paired t-test.

RESULTS:

During the acceleration phase, incisor movement was fastest in the corticosteroid group, followed by vitamin D, PGE₂, positive control, and negative control (P<0.001). In contrast, relapse was lowest in the negative control, positive control, and PGE₂ groups, and higher in vitamin D and corticosteroid groups (P<0.001). Histological findings were in the same line with the dental measurements. No harms were detected.

CONCLUSION:

Local application of corticosteroid, vitamin D, and PGE₂ enhanced orthodontic tooth movement. While corticosteroid produced the greatest acceleration, PGE₂ was associated with the least subsequent relapse.

01 Mar 2026·Journal of Physiological Sciences

EP4 stimulation promotes cell adhesion and migration via IL-6 signaling in oral squamous cell carcinoma

Article

Author: Hayashi, Chihiro ; Endo, Michiko ; Nagao, Kagemichi ; Ishikawa, Yoshihiro ; Fujita, Takayuki ; Fukae, Wakana ; Umemura, Masanari ; Yokoyama, Utako ; Oguri, Sneri ; Iida, Yu ; Mitsudo, Kenji ; Nagasako, Akane ; Ishikawa, Soichiro

Oral squamous cell carcinoma cell (OSCC) comprises malignant neoplasms arising within the oral cavity. Early-stage detection is associated with favorable prognosis, whereas progression to advanced stages with lymph node metastasis significantly worsens outcomes. We previously reported that the prostaglandin E₂ (PGE₂) receptor EP4 regulates OSCC migration. RNA sequencing reanalysis suggested that EP4 stimulation is strongly associated with cell migration and adhesion, with interleukin-6 (IL-6) emerging as a central mediator of these processes. In OSCC cells, ONO-AE1-437 (EP4 agonist) increased IL-6 mRNA expression and protein secretion. EP4-overexpressing cells showed increased IL-6 expression without stimulation, further enhanced by ONO-AE1-437 or PGE₂. xCELLigence demonstrated that PGE₂ promoted cell adhesion, which was suppressed by ONO-AE3-208 (EP4 antagonist) and Tocilizumab (IL-6 inhibitor). Scratch and transwell assays revealed enhanced migration under PGE₂ and ONO-AE1-437, blocked by IL-6 inhibition. These results suggest that EP4 promotes cell adhesion and migration through IL-6 in OSCC cells. (147 words).

01 Mar 2026·THERIOGENOLOGY

Time-dependent intrafollicular cyclooxygenase (COX) inhibition with prostaglandin: Effects on bovine ovulation and follicular fluid extracellular vesicles miRNAs

Article

Author: Vieira, Arnaldo Diniz ; de Castro, Natalia Ávila ; Gonçalves, Paulo Bayard Dias ; Rodrigues, Pedro Henrique de Oliveira Swartele ; Pegoraro, Lígia Margareth Cantarelli ; Maggi, Gabriel ; da Silveira, Juliano Coelho ; Ferst, Juliana Germano ; Lazzari, Jéssica ; Mondadori, Rafael Gianella ; de Moraes, Fabiane Pereira ; Gasperin, Bernardo Garziera ; Vargas Júnior, Sérgio Farias

Prostaglandins (PGs), specifically prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α), are critical regulators of the periovulatory cascade in cattle. While their roles are established, their precise, time-sensitive application for ovulation induction and rescue remains under investigation. We evaluated whether exogenous PGE2 and PGF2α, alone or combined, modulate ovulation and whether flunixin meglumine (FM), a nonsteroidal anti-inflammatory drug and COX inhibitor, reliably generates ovulation-block models. Experiments were conducted in cyclic Bos taurus cows. Estrous cycles were synchronized using intravaginal progesterone (P4) device (IVD), estradiol benzoate, cloprostenol sodium, and GnRH analogs. In Experiment 1, the effects of intrafollicular (IFI) of PGE2 alone or in combination with PGF2α on ovulation timing and luteal P4 production were evaluated. Experiments 2-4 examined FM-induced ovulation blockade via intramuscular (IM), intraovarian (IO), or IFI administration. Experiments 5-6 examined whether IFI prostaglandins reverse FM-induced blockade at defined periovulatory windows (16 h and 22 h post-GnRH). Experiment 7 evaluated extracellular vesicles (EV) from follicular fluid (FF) after systemic FM, including miRNA profiling. Ovulation timing was monitored by ultrasonography and luteal function by serum P4. In Experiment 1, IFI PGE2 or PGE2+PGF2α did not advance ovulation (median 66 h for PG groups vs. 42 h for control), but PGE2 increased serum P4 (P = 0.0014). Systemic IM FM (≈75-80 % ovulation) and IO FM (100 % ovulation) did not consistently block ovulation (Experiments 2-4), whereas IFI FM at 22 h post-GnRH inhibited ovulation in all treated cows (Experiment 6). Co-administration of prostaglandins at 16 h did not significantly reverse FM blockade (Experiment 5), but PGE2 partially restored ovulation at 22 h (44 % ovulated; P = 0.04), closer to the physiological PG peak (Experiment 6). Four miRNAs (bta-miR-584, bta-miR-369-5p, bta-miR-218, bta-miR-411c-5p) were downregulated in FF EV after FM, which were mapped to eight pathways pertinent to follicular rupture and PG-linked mechanisms. In conclusion, exogenous prostaglandins did not hasten ovulation, although PGE2 exerted a luteotropic effect. IFI FM administered near the late periovulatory window effectively blocked follicular rupture, and timely IFI PGE2 partially rescued FM-inhibited ovulation. Systemic FM also modulated FF EV miRNAs, suggesting pathway-level mechanisms underlying ovulatory failure.

News (Medical) associated with Dinoprostone

17 Feb 2026

·www.prnewswire.com

Renowned Developmental Biologist Wins March of Dimes Prize

ARLINGTON, Va., Feb. 17, 2026 /PRNewswire/ -- March of Dimes, a national leader in maternal and infant health research, today announced leading hematologist and stem cell scientist Dr. Leonard Zon as the winner of the 2026 March of Dimes Richard B Johnston Jr, MD Prize for his work in developmental biology. Dr. Zon's pioneering work has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including in pregnancy, and breakthrough treatments for genetic blood disorders affecting babies and children. Dr. Zon, Director of the Stem Cell Research Program at Boston Children's Hospital and the Grousbeck Professor of Pediatric Medicine at Harvard Medical School, is an acclaimed physician-scientist who has pioneered the use of the zebrafish as a model to study human disease with a focus on blood diseases and cancers affecting newborns and kids. In 1993, spurred by his desire to understand how blood develops and to mitigate rare yet devastating genetic blood diseases, Dr. Zon turned to the zebrafish, a 1.5-inch tropical fish with horizontal stripes, transparent embryos, and the ability to lay 300 embryos a week. The unique sea creature has helped him make remarkable findings about human biology and disease treatment. Among them, he and his team have illuminated the pathways of blood development in embryos, leading to a deeper understanding of rare blood diseases, including in pregnancy; discovered ferroportin, the iron transporter gene that delivers the crucial micronutrient from mother to baby; and identified a growth factor that exponentially grows stem cell populations for use in gene therapies for children with blood disorders, including sickle cell anemia. The March of Dimes Richard B Johnston Jr, MD Prize recognizes scientists whose work in developmental biology has transformed our understanding of human health. Dr. Zon's use of developmental biology to illuminate how blood forms in embryos exemplifies this mission, with direct applications to pregnancy complications and childhood diseases. "Dr. Zon's groundbreaking work using the zebrafish to study human disease has resulted in truly amazing insights about the most devastating genetic disorders and cancers affecting the smallest patients," said March of Dimes Chief Scientific Advisor Dr. Emre Seli. "Incredibly, Dr. Zon has balanced seeing sick kids in the clinic with groundbreaking laboratory discoveries about pediatric disorders that have repeatedly stumped scientists. His zebrafish work at the intersection of blood, cancer, genetics and induced pluripotent stem cells has transformed the way we understand and treat human disease." One of the first scientists to study zebrafish for the purposes of human disease, Dr. Zon led a team in the late 1990s that discovered five human genes never before implicated in blood diseases. The breakthrough electrified the field of hematology and crystallized zebrafish as not only a reliable — but an outstanding — model for human disease. Of the five novel genes Dr. Zon's team discovered, the most significant was the discovery of ferroportin, the iron transporter gene, in 2000. The gene ensures iron, and thereby oxygen-carrying hemoglobin, is delivered from mother to baby through the placenta. This discovery transformed understanding of iron deficiency and anemia of pregnancy, a common condition worldwide which can lead to preterm birth and low birth weight. The finding opened new avenues for preventing and treating maternal anemia and its effects on fetal development. Dr. Zon, who founded the International Society for Stem Cell Research in 2002, is also behind a transformative discovery around stem cells to treat blood disorders affecting children and babies. In 2007, his lab revealed that prostaglandin E2 could dramatically grow zebrafish stem cell populations. Human clinical trials in 2013 confirmed the lipid's power: adding it to donor umbilical cord blood increased the recipient's stem cell populations by 400%, vastly improving transplant success for leukemia patients. Today, the prostaglandin discovery is routinely used in stem cell gene therapy to treat genetic blood diseases in children, including sickle cell anemia, thalassemia, and primary immunodeficiencies, and has enabled advances in gene therapy techniques used by research teams worldwide. Dr. Zon's discoveries continue to yield new treatments. His zebrafish research has led to a novel therapeutic for Diamond-Blackfan anemia now approaching human clinical trials, and a treatment to treat a pediatric disease called spinal muscular atrophy, developed by a company he founded, is currently under Food and Drug Administration review. "Ever since my first experience working with leukemia patients early in my research career, I've been trying to uncover the mysteries of blood to help those affected by blood and other diseases," said Dr. Zon. "So, to be instrumental in the discovery of new pathways that underscore blood development in embryos and to have a real impact on diseases affecting kids and babies, that's priceless. And to do it with the fascinating zebrafish and be honored for it is icing on the cake." About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can have the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit marchofdimes.org or nacersano.org for more information. Find us on Facebook and follow us with #marchofdimes and @marchofdimes. SOURCE March of Dimes 21% more press release views with Request a Demo

Gene Therapy

27 Jan 2026

·www.businesswire.com

Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia

SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, immunological and fibrotic diseases, today announced outcomes from its Type C meeting with the Food and Drug Administration (FDA). Epirium has received written feedback from the FDA on its Phase 2b trial plan to evaluate MF-300, an oral 15-PGDH enzyme inhibitor for the treatment of age-related sarcopenia. Epirium has previously completed a positive Phase 1 clinical trial of MF-300, including older adult cohorts. Key Outcomes from the FDA Type C Meeting Reached concurrence with FDA on patient population, primary and secondary efficacy endpoints, treatment duration and dosing regimen of MF-300. Agreement that the efficacy endpoints evaluated in the Phase 2b study will inform Phase 3 endpoint selection. Agreement that a Fast Track Designation request may be submitted for MF-300 as a treatment for sarcopenia. Based on the positive outcome of this Type C meeting, Epirium will continue its plans to initiate a 6-month, randomized, double-blind, placebo-controlled, multi-center Phase 2b study designed to assess the safety and efficacy of MF-300 in patients diagnosed with age-related sarcopenia in the second half of 2026. The Company also plans to file an application for Fast Track Designation which, if accepted, will allow greater access to FDA interaction during MF-300 development for sarcopenia and enable priority review. “We are pleased with the positive outcome of our End-of-Phase 1 meeting with the FDA, which provided constructive guidance on our development strategy for MF-300 in sarcopenia,” said Alex Casdin, Chief Executive Officer of Epirium. Mr. Casdin added, “Epirium and the FDA are in broad agreement on the major aspects of the proposed Phase 2b clinical trial for MF-300, a first-in-class oral treatment for sarcopenia. With alignment on key elements of our trial, we plan to advance MF-300 into the next stage of clinical evaluation to further assess its safety and efficacy in support of a future Phase 3 program.” “In the absence of approved pharmacologic therapies or established regulatory pathways for sarcopenia, alignment with the FDA on a Phase 2b trial design represents an important milestone for the field,” said Dr. Jose Garcia, M.D., Ph.D., Professor, Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington School of Medicine. “As sarcopenia represents a significant and growing unmet medical need, this agreement is a meaningful step toward advancing therapeutic options for patients affected by age-related muscle loss and weakness.” Phase 2b Study Details The planned Phase 2b study is a 6-month, randomized, double-blind, placebo-controlled, multi-center trial designed to assess the safety and efficacy of MF-300 in approximately 200 patients diagnosed with sarcopenia. A comprehensive package of efficacy endpoints will assess the effect of MF-300 on muscle function, muscle strength and quality of life. The Company expects to begin enrolling patients into the trial in the second half of 2026. About MF-300 MF-300 is an investigational, first-in-class, orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor currently in development for the treatment of sarcopenia, or age-related muscle weakness. MF-300 reversibly occupies the prostaglandin E2 (PGE2) binding site of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). 15-PGDH metabolically degrades PGE2, generating non-functional PGE2 metabolites, and is transcriptionally upregulated in aged muscle. Preclinical data show that PGE2 plays a crucial role in promoting aged muscle strength by improving muscle quality (i.e., muscle strength independent of muscle mass) as well as function of the neuromuscular junction. In preclinical studies, oral administration of MF-300 increases physiologic levels of PGE2 in skeletal muscle in rats and it increases muscle force and improves muscle quality in aged mice. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function in sarcopenia. In a Phase 1 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MF-300 in younger and older adults, the primary safety endpoint was achieved, the PD profile demonstrated dose-related target engagement and biologic activity, and the PK profile of MF-300 supports once daily dosing. About Sarcopenia The Food and Drug Administration (FDA) estimates that up to a third of Americans over the age of 60 are affected by sarcopenia, a disease that increases the risk of falls, fractures, disability and all-cause mortality. Despite sarcopenia’s widespread prevalence and serious health implications, there are currently no FDA-approved therapies available to treat sarcopenia, highlighting the significant unmet medical need for this disease. About Epirium Bio Epirium, a biopharmaceutical company based in San Diego, California, has identified and established an IP-protected platform of orally bioavailable small molecules that constitute a new class of therapeutics with the potential to improve function in neuromuscular diseases, including sarcopenia and spinal muscular atrophy. Epirium has also generated preclinical data across multiple therapeutic areas with significant unmet medical need, including immunology and fibrosis, which Epirium’s development pipeline has the potential to address. To learn more about Epirium, please visit www.epirium.com and follow us on LinkedIn.

Phase 2Clinical ResultFast TrackPhase 1

08 Jan 2026

·www.biospace.com

Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia

As with the younger study participants, no safety concerns or dose limiting toxicities were observed in older adults and pharmacodynamic analysis continued to demonstrate evidence of target engagement together with a biologic effect SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced additional results from the older adult follow-on cohorts from its completed Phase 1 trial evaluating MF-300, a novel therapy in development for primary or age-related sarcopenia. In the older cohorts, the study met its primary safety endpoint, and the evaluated dose of MF-300 - corresponding to the maximum estimated pharmacologic effect - was generally well tolerated, with no early discontinuations. In older adults, MF-300 continued to demonstrate the desired pharmacodynamic (PD) responses with a pro with the younger study participants. PD responses were observed early and sustained over time, with effects that differentiated from placebo, supporting target engagement and biologic activity. Pharmacokinetic (PK) analyses demonstrated exposures consistent with younger adults, the observed half-life supporting convenient once-daily oral dosing. “We are encouraged by the success of our Phase 1 study. In the age group targeted for our planned Phase 2 study in age-related sarcopenia, MF-300 results were consistent with the favorable safety, PK and PD findings observed in younger adults. Notably, all older participants receiving MF-300 demonstrated reductions in urinary PGE2 metabolites consistent with levels associated with maximal gains in muscle force in aged mouse models, along with substantial increases in urinary PGE2 that were comparable to increases observed in human muscle tissue after exercise,” said Alex Casdin, Chief Executive Officer of Epirium. Mr. Casdin added, “These Phase 1 results in older adults support advancing MF-300 into a Phase 2 safety and efficacy study in patients with age-related sarcopenia, a disease affecting over 20 million seniors, for which there are no FDA-approved therapies.” Phase 1 Study Details The randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial was designed to assess the safety, tolerability, PK and PD of MF-300 in healthy adults, including younger (≥18 to ≤65 years of age) and older (>65 to ≤75 years of age) participants. A total of 100 healthy participants were enrolled and received oral administration of MF-300 or placebo as part of single- and multiple-ascending (once daily dosing for 5 days) dose cohorts. MF-300 was well tolerated across all cohorts, with no serious adverse events and all participants completed the study. Most adverse events were assessed as mild. PK analyses demonstrated a half-life supporting a convenient once-daily oral administration. Evidence of on-target biological activity was observed, in a dose-dependent manner, as measured by changes in PGE2 and its metabolites, guiding dose selection for Phase 2. Findings were consistent between younger and older participants. The company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with sarcopenia in mid-2026. About MF-300 MF-300 is an investigational, first-in-class, orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor currently in development for the treatment of sarcopenia, or age-related muscle weakness. MF-300 reversibly occupies the prostaglandin E2 (PGE2) binding site of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). 15-PGDH metabolically degrades PGE2, generating non-functional PGE2 metabolites, and is transcriptionally upregulated in aged muscle. Preclinical data show that PGE2 plays a crucial role in promoting aged muscle strength by improving muscle quality (i.e., muscle strength independent of muscle mass) as well as function of the neuromuscular junction. In preclinical studies, oral administration of MF-300 increases physiologic levels of PGE2 in skeletal muscle in rats and it increases muscle force and improves muscle quality in aged mice. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function in sarcopenia. About Sarcopenia The U.S. Food and Drug Administration (FDA) estimates that up to a third of Americans over the age of 60 are affected by sarcopenia, a disease that increases the risk of falls, fractures, disability and all-cause mortality. Despite sarcopenia’s widespread prevalence and serious health implications, there are currently no FDA-approved therapies available to treat sarcopenia, highlighting the significant unmet medical need for this disease. About Epirium Bio Epirium, a biopharmaceutical company based in San Diego, California, has identified and established an IP-protected platform of orally bioavailable small molecules that constitute a new class of therapeutics with the potential to improve function in neuromuscular diseases, including sarcopenia and spinal muscular atrophy. Epirium has generated preclinical data in a broader scope of indications with significant unmet medical need, including fibrosis, which Epirium’s development pipeline has the potential to address. To learn more about Epirium, please visit and follow us on LinkedIn . Contacts Email: info@epirium.com

Clinical ResultPhase 1Phase 2

100 Deals associated with Dinoprostone

External Link

KEGG	Wiki	ATC	Drug Bank
D00079	Dinoprostone	G02AD02	DB00917

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Induced Abortion	United States	Pfizer Inc.	23 Aug 1977
Labor, Induced	Japan	Maruishi Pharmaceutical Co., Ltd.	13 Jan 1973

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EUCTR2011-000933-35-FR \| NCT01765881 (Pubmed \| Int J Gynaecol Obstet)	Phase 2	-	790	Vaginal Misoprostol (PGE1) (25μg)	augbksfhgz(neuxjvbnci) = gceitnecqj huiumejwnj (bplsetbrch ) View more	-	01 Aug 2022
				Dinoprostone Pessary (PGE2) (10μg)	augbksfhgz(neuxjvbnci) = fxbxiwrolz huiumejwnj (bplsetbrch ) View more
NCT03806231 (CTgov)	Phase 3	Labor, Induced	8	Outpatient Dinoprostone 10mg (Outpatient Cervical Ripening)	odhmxrrcnx(ddsitlbnxe) = wklnnxvhzz veabiiqmyb (rsmvenmuln, lvnjyvxszl - izvafoanrs) View more	-	05 Sep 2021
				Inpatient Dinoprostone 10 mg (Inpatient Cervical Ripening)	odhmxrrcnx(ddsitlbnxe) = gimsrmxctk veabiiqmyb (rsmvenmuln, onnopuglne - zajroepgnw) View more
NCT01765881 (Pubmed \| Am J Obstet Gynecol)	Phase 2	Labor, Induced	1,674	Vaginal Misoprostol (PGE1) (25 μg)	bvhdyfawjj(dozahslqug) = bidlaydfap dposbqwgbw (vqrbjafqhu ) View more	Positive	19 Apr 2021
				Slow-release Dinoprostone (PGE2) Pessary (10 μg)	bvhdyfawjj(dozahslqug) = mwqyqettzb dposbqwgbw (vqrbjafqhu ) View more
NCT01402050 (CTgov)	Not Applicable	Labor, Induced	376	FOLEY BALLOON (FOLEY BALLOON)	zghwpfuuqm(prlsrqhrjn) = jdqzpiheur dqufdogpmh (dewfresahu, iyczeocntm - sesjcxzwdx) View more	-	06 Feb 2020
				CERVIDIL (CERVIDIL)	zghwpfuuqm(prlsrqhrjn) = dbumaocfpj dqufdogpmh (dewfresahu, kcmmchdjdp - vkjkreorwy) View more
NCT03199820 (PROBIT-F, Pubmed \| Pilot Feasibility Stud)	Phase 4	Labor, Induced	274	Prostaglandin insert dinoprostone (Cervical ripening balloon catheter (CRB))	lqevtojykt(jekteeehkr) = qslkoywrms dxtazqzbes (ybewcdfwef )	-	01 Jan 2020
				Vaginal dinoprostone (Propess)	lqevtojykt(jekteeehkr) = ronyvlpvoh dxtazqzbes (ybewcdfwef )
NCT01402050 (Pubmed \| Obstet Gynecol)	Not Applicable	Labor, Induced	376	Foley catheter	htydpbbfum(upsoztutbc) = owznfxqimc wecbqgpzyb (macsluyphw ) View more	-	01 Jun 2014
				Dinoprostone vaginal insert	htydpbbfum(upsoztutbc) = varvbcnlya wecbqgpzyb (macsluyphw ) View more
ACTRN:12609000420246 (Pubmed \| BMC Pregnancy Childbirth)	Phase 4	Labor, Induced	101	Inpatient vaginal PGE2 gel	exeslgzblj(kezrxiebic) = gohxevllsv ccefcbltvw (iczrotqfaf ) View more	-	29 Jan 2013
NCT01635439 (CTgov)	Phase 3	Labor Pain	200	Propess (Propess)	iasptdlint(rdesshfizy) = mjrhwswrcq ohlsitenbc (qewruxchqv, 5.7) View more	-	04 Oct 2012
				Prostin E2 (Prostin E2)	iasptdlint(rdesshfizy) = wkqfxenkki ohlsitenbc (qewruxchqv, 5.3) View more
ISRCTN78483537 (Pubmed 1 \| Pubmed 2 \| BJOG)	Not Applicable	Labor, Induced	-	Prostaglandin E2 vaginal gel	llwobwvrjw(tywgqtwaox) = oqgjizffrz jznpveyejg (eupmtdhzgy, 690 - 2280)	Positive	01 May 2011
				Vaginal tablets	llwobwvrjw(tywgqtwaox) = bmoqewkkse jznpveyejg (eupmtdhzgy, 960 - 2640)
ISRCTN74376345 (Pubmed \| Obstet Gynecol)	Not Applicable	Fetal Membranes, Premature Rupture	201	Concurrent vaginal dinoprostone and oxytocin	khhybgxkqm(tzvgujyumt) = kslmadflaq fyoypyhimt (iorcaoviej ) View more	-	01 May 2009
				Oxytocin infusion	khhybgxkqm(tzvgujyumt) = erlcwsidkl fyoypyhimt (iorcaoviej ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dinoprostone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation